Wall Street analyst estimates for Lite Strategy, Inc. (LITS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Valuation Ratios
| Price / Book | 0.14 |
| EV / EBITDA | -2.58 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $34.8M | $40.7M | $48.8M | $65.3M | 0 |
| Cost of Revenue | $1.4M | 0 | 0 | 0 | $368000 |
| Gross Profit | $33.4M | $40.7M | $48.8M | $65.3M | -$368000 |
| Research & Development | $69.4M | $85.6M | $52.5M | $16.6M | $3.9M |
| Selling, General & Admin | $24.4M | $30.5M | $33.1M | $23.3M | $13.5M |
| Operating Expenses | $93.8M | $116.2M | $85.6M | $50.8M | $17.1M |
| Operating Income | -$60.4M | -$75.5M | -$36.8M | $14.5M | -$17.5M |
| EBITDA | -$41.0M | -$75.2M | -$36.4M | $25.8M | -$17.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$41.3M | -$54.5M | -$31.8M | $17.8M | -$15.9M |
| Income Tax | $8000 | 0 | 0 | 0 | 0 |
| Net Income | -$41.3M | -$54.5M | -$31.8M | $17.8M | -$15.9M |
| EPS | $-12.21 | $-10.04 | $-4.78 | $2.67 | $-2.39 |
| EPS (Diluted) | $-12.00 | $-9.99 | $-4.78 | $2.67 | $-2.39 |
| Shares Outstanding (Diluted) | $5.7M | $6.3M | $6.7M | $6.7M | $6.7M |
Price
| Price | $1.02 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACET · ACRV · HOWL · IMUX · IOBT · NTRB · PMVP
Explore sector: Healthcare · Biotechnology
More sections of LITS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks